Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis Patients
Links shared publicly online about this topic.
- 1,356total visits
Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis Patients
Aradigm Corporation (OTCBB:ARDM) (the Company) announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an
View full resource at medicalnewstoday.com
Tags: Bronchiectasis, Clinical Trial, Antibiotic, Cipro, Ciprobay
Most Recently Shared on February 25, 2010 at 4:14 pm By:
Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis... http://mnt.to/3y6r
Also Shared By:
Advertisement
MNT Asthma News
@mnt_asthma
Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis... http://mnt.to/3y6r
1 year ago...